Peter R. Carroll, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Peter R. Carroll, MD, MPH

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF
Ken and Donna Derr—Chevron Distinguished Professorship in Prostate Cancer

Phone: (415) 353-7171 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

View on UCSF Profiles

Cancer Center Membership

Program Member » Prostate Cancer

Additional Websites


Education

University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008
 


Professional Experience

  • 1984-1986
    Fellow, Urology Service, Memorial Sloan-Kettering Cancer Center
  • 1986-1992
    Assistant Professor in Residence, Dept. of Urology, University of California, S.F
  • 1992-1993
    Associate Professor, Dept. of Urology, University of California, San Francisco
  • 1996-present
    Program Leader, Program in Urologic Oncology, UCSF Cancer Center
  • 1996-present
    Professor and Chair, Department of Urology, UCSF, San Francisco, CA
  • 2003-present
    Surgeon-in-Chief, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2006-present
    Associate Director of Clinical Services and Strategic Planning, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2006-present
    Associate Dean, UCSF School of Medicine

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS One. 2015; 10(7):e0132343.
    View on PubMed
  2. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015 Jul 7; 314(1):80-2.
    View on PubMed
  3. Filippou P, Welty CJ, Cowan JE, Perez N, Shinohara K, Carroll PR. Immediate Versus Delayed Radical Prostatectomy: Updated Outcomes Following Active Surveillance of Prostate Cancer. Eur Urol. 2015 Sep; 68(3):458-63.
    View on PubMed
  4. Dall'Era M, Carroll P. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer? J Urol. 2015 Sep; 194(3):615-6.
    View on PubMed
  5. Hilmer SN, Seale JP, Carroll PR. A comparison of medical and pharmacy students' knowledge and skills of pharmacology and pharmacotherapy. Br J Clin Pharmacol. 2015 Jun; 79(6):1028-9.
    View on PubMed
  6. Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015 Aug; 75(11):1206-15.
    View on PubMed
  7. Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernán MA. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May; 51(7):817-24.
    View on PubMed
  8. Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR. Impact of Age on Quality-of-life Outcomes After Treatment for Localized Prostate Cancer. Eur Urol. 2015 Sep; 68(3):480-6.
    View on PubMed
  9. Hussein AA, Punnen S, Zhao S, Cowan JE, Leapman M, Tran TC, Washington SL, Truesdale MD, Carroll PR, Cooperberg MR. Current Use of Imaging after Primary Treatment of Prostate Cancer. J Urol. 2015 Jul; 194(1):98-104.
    View on PubMed
  10. Schreuder LJ, Carroll P, Muwanguzi-Karugaba J, Kokoczka R, Brown AC, Parish T. Mycobacterium tuberculosis H37Rv has a single nucleotide polymorphism in PhoR which affects cell wall hydrophobicity and gene expression. Microbiology. 2015 Apr; 161(Pt 4):765-73.
    View on PubMed
  11. Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes. J Urol. 2015 Jul; 194(1):85-90.
    View on PubMed
  12. Bangma CH, Valdagni R, Carroll PR, van Poppel H, Klotz L, Hugosson J. Active Surveillance for Low-risk Prostate Cancer: Developments to Date. Eur Urol. 2015 Apr; 67(4):646-8.
    View on PubMed
  13. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10.
    View on PubMed
  14. Gerstenberger JP, Bauer SR, Van Blarigan EL, Sosa E, Song X, Witte JS, Carroll PR, Chan JM. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate. 2015 Jan; 75(1):60-9.
    View on PubMed
  15. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
    View on PubMed
  16. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11).
    View on PubMed
  17. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep; 12(9):1211-9; quiz 1219.
    View on PubMed
  18. Klein EA, Cooperberg MR, Carroll PR. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur Urol 2014;66:550-60. Eur Urol. 2014 Dec; 66(6):e117-8.
    View on PubMed
  19. Akaza H, Kim CS, Carroll P, Choi IY, Chung BH, Cooperberg MR, Hirao Y, Hinotsu S, Horie S, Lee JY, Namiki M, Ng CF, Onozawa M, Ozono S, Ueno S, Umbas R, Ye D, Zhu G. Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int. 2014; 2(2):50-69.
    View on PubMed
  20. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 2014; 9(6):e98597.
    View on PubMed

Go to UCSF Profiles, powered by CTSI